los criterios de elegibilidad actuales del seguro popular para recibir tratamiento para el virus de la hepatitis c
Clicks: 153
ID: 191186
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
153 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #138 of 219 articles by views in journal of anatomy
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Pocas cosas han avanzado tanto como el tratamiento contra el virus de la hepatitis C (VHC). Se tienen antivirales de acción directa (AAD) con los que se obtienen respuestas virales sostenidas (RVS) mayores a 90%, pero el costo de estos medicamentos es prohibitivo para los sistemas de salud…
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (50 words).
Try re-searching for a better abstract.
| Reference Key |
moctezuma-velzquez2016saludlos
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Carlos Moctezuma-Velázquez;Juan Francisco Sánchez-Ávila;Ignacio García-Juárez;Luis Federico Uscanga-Domínguez;David Kershenobich-Stalnikowitz |
| Journal | journal of anatomy |
| Year | 2016 |
| DOI |
10.21149/spm.v58i6.7865
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.